KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Raw Materials (2017 - 2025)

Bionano Genomics' Raw Materials history spans 7 years, with the latest figure at $6.1 million for Q3 2025.

  • For Q3 2025, Raw Materials rose 68.93% year-over-year to $6.1 million; the TTM value through Sep 2025 reached $6.1 million, up 68.93%, while the annual FY2024 figure was $6.7 million, 11.26% down from the prior year.
  • Raw Materials for Q3 2025 was $6.1 million at Bionano Genomics, down from $6.4 million in the prior quarter.
  • Across five years, Raw Materials topped out at $8.9 million in Q2 2024 and bottomed at $837000.0 in Q2 2022.
  • The 5-year median for Raw Materials is $5.8 million (2023), against an average of $5.0 million.
  • The largest annual shift saw Raw Materials plummeted 60.95% in 2021 before it skyrocketed 641.22% in 2023.
  • A 5-year view of Raw Materials shows it stood at $4.6 million in 2021, then rose by 14.41% to $5.3 million in 2022, then skyrocketed by 42.26% to $7.6 million in 2023, then fell by 11.26% to $6.7 million in 2024, then fell by 9.41% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Raw Materials are $6.1 million (Q3 2025), $6.4 million (Q2 2025), and $6.6 million (Q1 2025).